We are pleased to announce the signature today of a partnership with ProQR Therapeutics, a pioneer in next-generation RNA technology, for the further development of 2 projects: sepofarsen and ultevursen. This acquisition represents a new step for Théa in the research and treatment of rare genetic eye diseases.
A fully dedicated team of experts specialized in hereditary retinal diseases (IRD) will be set up to manage these two innovative projects. Details of the next steps will be announced in the coming weeks.
This strategic collaboration between Théa and ProQR Therapeutics opens up exciting new prospects in the field of eye care.
To read the press release, click here.
